Summary
- Current Price
- As of today, IDXX price is $676.21, down -1.95% on
- Current Price All-Time High
- IDXX price is currently -12.18% below its historical high of $769.98 set on
- Market Cap
- IDXX current market cap is $53B, down -3.39% year-over-year
- PE Ratio
- IDXX current PE ratio is 45.58
- Revenue
- IDXX current annual revenue is $4.30B, up +10.42% year-over-year
- Next Earnings
- The next earnings release for IDXX is on
Profile
| Metric | Value |
|---|---|
| Full Name | IDEXX Laboratories, Inc. |
| Ticker | NASDAQ: IDXX |
| Exchange | NASDAQ |
| Sector | Healthcare |
| Industry | Diagnostics & Research |
| Country | United States |
| IPO | |
| Indexes | |
| Website | idexx.com |
| Employees | 11,000 |
Key Metrics
| Metric | Value | Date |
|---|---|---|
| Price | $676.21 | |
| Price, 1D Change | -1.95% | |
| Market Cap | $53B | |
| - | ||
| PE Ratio | 45.58 | |
| Beta | 0.77 | |
| Revenue | $4.30B | |
| Revenue, 1Y Change | +10.42% | |
| EPS | $13.08 | |
| EPS, 1Y Change | +22.60% |
Chart
SUGGESTED SERIES
Events
| Metric | Value | Date |
|---|---|---|
| Next Earnings | ||
| Last Qtr. Earnings | ||
| Last Ann. Earnings | ||
| Last Ex-Dividend | N/A | N/A |
| Next Ex-Dividend | N/A | N/A |
| Last Split | 2:1 | |
| Next Split | N/A | N/A |
| Last Ticker Change | N/A | N/A |
| Next Ticker Change | N/A | N/A |
🔒 Log In To Unlock Full Data
Estimates
| Metric | Value | Date |
|---|---|---|
| EPS | $13.08 | |
| EPS Estimate | $15.02 | |
| EPS Est. Change | +14.90% | |
| Revenue | $4.30B | |
| Revenue Estimate | $4.76B | |
| Revenue Est. Change | +10.50% | |
| Current Price | $676.21 | |
| Price Target | $717.50 | - |
| Price Tgt. Change | +6.11% | - |
🔒 Log In To Unlock Full Data
EPS
| Year | Estimate | Reported | Surprise / Exp. |
|---|---|---|---|
| $10.69 | $10.67 | -0.25% | |
| $12.93 | $13.08 | +1.13% | |
| $15.02 | N/A | +14.90% | |
| $16.89 | N/A | +29.19% |
Revenue
| Year | Estimate | Reported | Surprise / Exp. |
|---|---|---|---|
| $3.88B | $3.90B | +0.37% | |
| $4.28B | $4.30B | +0.44% | |
| $4.76B | N/A | +10.50% | |
| $5.18B | N/A | +20.31% |
🔒 Log In To Unlock Full Data
Performance
| Metric | Value | Date |
|---|---|---|
| Price, 1Y | -1.91% | |
| Price, 3Y | +42.98% | |
| Market Cap, 1Y | -3.39% | |
| Market Cap, 3Y | +35.61% | |
| Revenue, 1Y | +10.42% | |
| Revenue, 3Y | +27.81% | |
| EPS, 1Y | +22.60% | |
| EPS, 3Y | +62.90% |
🔒 Log In To Unlock Full Data
Technicals
| Metric | Value | Date |
|---|---|---|
| Current Price | $676.21 | |
| SMA 200 | $573.48 | |
| SMA 50 | $579.87 | |
| EMA 200 | $581.79 | |
| EMA 50 | $609.52 | |
| MACD | $34.81 | |
| Beta | 0.77 | |
| ATR | $22.60 | |
| 14-Day RSI | 59.78 | |
| 10-Day Volatility | 30.74% |
Dividends
| Metric | Value | Date |
|---|---|---|
| - | N/A | |
| Upcoming | N/A | N/A |
| - | ||
| - | ||
| $0.00 | ||
| 0.00% |
🔒 Log In To Unlock Full Data
Income & Profitability
| Metric | Value | Date |
|---|---|---|
| Revenue | $4.30B | |
| EPS | $13.08 | |
| Gross Profit | $2.66B | |
| Gross Margin | 61.82% | |
| Operating Income | $1.37B | |
| Operating Margin | 31.72% | |
| Net Income | $1.06B | |
| Net Margin | 24.62% | |
| EBITDA | $1.51B |
🔒 Log In To Unlock Full Data
Financial Health
| Metric | Value | Date |
|---|---|---|
| Debt To Equity | 0.61 | |
| 1.17 | ||
| 0.84 | ||
| - | ||
| 8 | ||
| 23.68 |
Valuations
| Metric | Value | Date |
|---|---|---|
| PE Ratio | 45.58 | |
| 11.43 | ||
| 28.50 | ||
| 32.43 | ||
| - | N/A |
Balance Sheet
| Metric | Value | Date |
|---|---|---|
| Book Value | $1.61B | |
| $180.07M | ||
| $3.35B | ||
| $1.34B | ||
| $1.75B | ||
| $1.15B | ||
| Total Debt | $976.06M | |
| $500.07M | ||
| $110.41M |
Expenses
| Metric | Value | Date |
|---|---|---|
| $3.24B | ||
| $1.30B | ||
| $1.64B | ||
| $0.00 | ||
| $145.18M | ||
| $0.00 | ||
| $264.73M |
Cash Flow
| Metric | Value | Date |
|---|---|---|
| $1.18B | ||
| -$136.24M | ||
| -$1.16B | ||
| Capex | $138.23M | |
| $1.04B |
Recent analyst updates
| Metric | Value | Date |
|---|---|---|
| UBS | → | |
| Morgan Stanley | → | |
| UBS | → | |
| JP Morgan | → | |
| Keybanc | ||
| Barclays | → | |
| UBS | → | |
| Citigroup | → | |
| UBS | → | |
| UBS | → |
Analyst sentiment
Institutional ownership
No data
Screeners with IDXX
FAQ
- What is the ticker symbol for IDEXX Laboratories, Inc.?
- The ticker symbol for IDEXX Laboratories, Inc. is NASDAQ:IDXX
- Does IDEXX Laboratories, Inc. pay dividends?
- No, IDEXX Laboratories, Inc. does not pay dividends
- What sector is IDEXX Laboratories, Inc. in?
- IDEXX Laboratories, Inc. is in the Healthcare sector
- What industry is IDEXX Laboratories, Inc. in?
- IDEXX Laboratories, Inc. is in the Diagnostics & Research industry
- What country is IDEXX Laboratories, Inc. based in?
- IDEXX Laboratories, Inc. is headquartered in United States
- When did IDEXX Laboratories, Inc. go public?
- IDEXX Laboratories, Inc. initial public offering (IPO) was on June 21, 1991
- Is IDEXX Laboratories, Inc. in the S&P 500?
- Yes, IDEXX Laboratories, Inc. is included in the S&P 500 index
- Is IDEXX Laboratories, Inc. in the NASDAQ 100?
- Yes, IDEXX Laboratories, Inc. is included in the NASDAQ 100 index
- Is IDEXX Laboratories, Inc. in the Dow Jones?
- No, IDEXX Laboratories, Inc. is not included in the Dow Jones index
- When was IDEXX Laboratories, Inc. last earnings report?
- IDEXX Laboratories, Inc.'s most recent earnings report was on November 2, 2026
- When does IDEXX Laboratories, Inc. report earnings?
- The next expected earnings date for IDEXX Laboratories, Inc. is February 1, 2027
Data Sources & References
- IDXX Official Website www.idexx.com
- Most Recent Annual Report (10-K) www.sec.gov/Archives/edgar/data/874716/000110465926008904/0001104659-26-008904-index.htm
- List of S&P 500 Companies www.spglobal.com/spdji/en/indices/equity/sp-500/#overview
- List of NASDAQ 100 Companies www.nasdaq.com/market-activity/quotes/nasdaq-ndx-index
- IDXX Profile on Yahoo Finance finance.yahoo.com/quote/IDXX
- IDXX Profile on NASDAQ.com www.nasdaq.com/market-activity/stocks/idxx
